NCT05647915 (BRAVO) is a Phase 4 clinical trial of Berberine plus lifestyle intervention in Obesity, sponsored by China National Center for Cardiovascular Diseases.

Who is sponsoring NCT05647915?

NCT05647915 is sponsored by China National Center for Cardiovascular Diseases.

What drugs are being tested in NCT05647915?

Interventions in NCT05647915: Berberine plus lifestyle intervention, Placebo plus lifestyle intervention.

What condition does NCT05647915 study?

NCT05647915 studies Obesity, Obesity, Abdominal, NAFLD.

Is NCT05647915 still recruiting?

NCT05647915 is currently completed. Last updated 29 January 2025.

Last reviewed 2025-01-29 · How we verify

NCT05647915: BRAVO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD

Completed Phase 4 Last updated 29 January 2025

What this trial tests

Phase 4 trial testing Berberine plus lifestyle intervention in Obesity in 337 participants. Completed in 9 August 2024.

Timeline

6 July 2023

Primary endpoint
9 August 2024

9 August 2024

Quick facts

Lead sponsor	China National Center for Cardiovascular Diseases
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	337
Start date	6 July 2023
Primary completion	9 August 2024
Estimated completion	9 August 2024
Sites	1 location across China

Drugs / interventions tested

Berberine plus lifestyle intervention — full drug profile →
Placebo plus lifestyle intervention

Conditions studied

Obesity — all drugs for Obesity →
Obesity, Abdominal — all drugs for Obesity, Abdominal →
NAFLD — all drugs for NAFLD →

Sponsor

China National Center for Cardiovascular Diseases — full company profile →

Who can join

18 and older, any sex, with Obesity or Obesity, Abdominal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine in reducing visceral and liver adipose tissue among individuals with obesity and non-alcoholic fatty liver disease (NAFLD) in China.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options.
Ren R, Liang X, Wei X. · · 2026 · PMID 42215843 · DOI 10.1186/s43556-026-00486-5
Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.
Lei L, Wang B, Zhao L, Li J, et al · · 2026 · PMID 41543854 · DOI 10.1001/jamanetworkopen.2025.54152
Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis.
Zhang CY, Liu S, Sui YX, Yang M. · · 2025 · PMID 41368119 · DOI 10.4254/wjh.v17.i11.113756

Verify or expand the search:

Other trials of Berberine plus lifestyle intervention

Trials testing the same drug.

NCT05749874 — Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus · Phase 4 · active not recruiting

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other China National Center for Cardiovascular Diseases trials

Trials by the same sponsor.

NCT07514988 — Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment · NA · not yet recruiting
NCT07476456 — Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death · not yet recruiting
NCT07302659 — Aortic No-Touch vs Partial Aortic Clamping in Off-Pump CABG · NA · recruiting
NCT07482683 — Predicting Post-Cardiac Surgery Acute Kidney Disease: A Machine Learning Approach · not yet recruiting
NCT06787430 — Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05647915 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China National Center for Cardiovascular Diseases
Last refreshed: 29 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05647915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing